ASN abstracts provide further views into the differentiation of Zerenex in ESRD patients and an important look into JT Torii's Phase III in CKD patients. We believe these data provide an important window into the Keryx Phase II data in CKD patients expected in early November. We are now including CKD in our valuation and raising our price target from $16 to $24. We recommend owning KERX into ASN (Nov. 5-10"
Interesting timing to put together a 8 buck upgrade in a couple of hours. I wonder how much they scooped up yesterday????? I'll take it but it makes ya wonder....Solid floor in now.. Weak hands , you were warned.